Hua Medicine (Shanghai) Ltd.
HKEX:2552.HK
Overview | Financials
Company Name | Hua Medicine (Shanghai) Ltd. |
Symbol | 2552.HK |
Currency | HKD |
Price | 1.71 |
Market Cap | 1,677,721,691 |
Dividend Yield | 0% |
52-week-range | 1.03 - 2.65 |
Industry | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Dr. Li Chen Ph.D. |
Website | https://www.huamedicine.com |
An error occurred while fetching data.
About Hua Medicine (Shanghai) Ltd.
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD